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Endometrial cancer is the most common gynecological malignancy and the fourth 
most frequently diagnosed cancer among women. The molecular changes that distinguish 
normal endometrium from endometrial carcinoma are not thoroughly understood. 
Identification of these changes could potentially aid in identifying at-risk women who are 
especially prone to develop endometrial cancer, such as obese women and women with 
Lynch Syndrome.  
A microarray analysis was performed using normal endometrium from thin and 
obese women and cancerous endometrium from obese women. We validated the differential 
expression of ten genes whose expression was significantly up-regulated or down-regulated 
using qRT-PCR. All of the genes had distinct expression levels depending on the 
endometrial carcinoma histotype. As a result, they could serve as molecular markers to 
distinguish between normal endometrium and endometrial cancer, as well as between low 
grade endometrial carcinomas and high grade endometrial carcinomas. 
Two of the ten genes validated, HEYL and HES1, are down-stream targets of the 
Notch signaling pathway. HEYL and HES1 were identified by microarray and qRT-PCR to 
have a significant decrease in expression in endometrial carcinomas compared to normal 
endometrium. We further analyzed the differential expression of other components of the 
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Notch signaling pathway, Notch4 and Jagged1. They were also identified by qRT-PCR to be 
significantly down-regulated in endometrial carcinomas compared to normal endometrium. 
Therefore, we believe the Notch signaling pathway to act as a tumor suppressor in 
endometrial carcinomas.  
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Chapter 1 
General Introduction 
 
Endometrial Cancer 
 Endometrial cancer (EC) is the most common gynecologic malignancy and the 
fourth frequently diagnosed cancer among women, with cancers of the breast, lung, and 
colon being more prevalent (1, 2). In 2012, an estimated 47, 130 women were diagnosed 
with endometrial cancer, with 8,010 deaths resulting from the disease (3).  
 Endometrial cancer can be differentiated into two broad categories. Type I cancers 
are of a well-differentiated, endometrioid subtype and comprise about 80% of endometrial 
cancers. They are low grade (grade 1 or grade 2) endometrioid endometrial 
adenocarcinomas (EECs) and typically arise in a background of hyperplasia. They are 
confined to the uterine wall, are minimally invasive, and have a higher survival rate. 
Additionally, type I cancers are often related to obesity, hormonal imbalance, and 
hyperlipidemia. Type II cancers are high-grade, poorly differentiated endometrial 
carcinomas and account for about 20% of ECs. They consist of high grade (grade 3) EECs, 
malignant mixed Mullerian tumors (MMMT) and papillary serous carcinoma (PSC). These 
cancers occur in older women, are not associated with high estrogen levels, and have a poor 
patient prognosis (1, 2). Clear cell carcinomas and undifferentiated carcinomas are also 
typically considered non-endometrioid tumors.  
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 Cancers generally develop after inactivation of tumor suppressor genes, 
overexpression of oncogenes, or defects in DNA repair damage. The development of both 
types of ECs is dependent on different molecular changes. The most common change in type 
I EC is the inactivation of PTEN, a tumor suppressor gene expressed in estrogen-primed 
environments (1, 2). PTEN has been reported to be altered in up to 83% of endometrioid 
carcinomas and 55% of precancerous lesions (2). Additionally, type I ECs are associated 
with mutations in β-catenin and K-RAS, as well as defects in DNA mismatch repair (2). 
Type II ECs typically exhibit aneuploidy and p53 mutations (2). Table 1 summarizes the 
common genetic alterations in endometrial cancer. Due to the differences in the molecular 
changes of both types of ECs, it is important to further investigate the differential gene 
expression profiles of various ECs and normal endometrial tissue.  
Table 1. Typical molecular alterations in Type 1 and 2 endometrial carcinomas.  
Genetic Alteration Type 1 Carcinomas (%) Type 2 Carcinoma (%) 
PTEN inactivation 50-80 (4) 10 (4) 
Microsatellite instability 20-40 (2) 0-5 (2) 
β-catenin mutation 20-40 (5) 0-3 (5) 
K-RAS mutation 15-30 (5) 0-5 (5) 
p53 mutation 10-20 (2) 80-90 (2) 
HER-2/neu 
overexpression 
10-30 (2) 40-80 (2) 
p16 inactivation  10 (2) 45 (2) 
E-(cadherin) 
decreased/loss expression 
10-20 (2) 60-90 (2) 
 
Prevention of Endometrial Cancer  
 Cancers such as ovarian and pancreatic cancers have no known precursor lesions and 
are currently almost impossible to prevent. Endometrial atypical complex hyperplasia is a 
precancerous condition that coexists with 40% of women who develop endometrial cancer 
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(6). This risk factor, in combination with Lynch Syndrome and obesity, are the most 
common factors associated with endometrial cancer development (6). 
 Lynch Syndrome (LS), an autosomal dominant hereditary syndrome, is the most 
common form of inherited predisposition to develop cancer (7). Lynch Syndrome results 
from germline mutations in DNA mismatch repair genes (7). LS patients are at a higher risk 
of developing certain cancers during their lifetime, including colorectal (52-82%), stomach 
(6-13%), ovary (4-12%), urinary tract (1-4%), and endometrial (25-60%). However, many 
patients do not realize they have a family history suggestive of Lynch Syndrome. Thus, it is 
especially important for physicians to ask about cancers in both maternal and paternal 
lineages and promote genetic counseling and testing. In the case that women are aware of 
having Lynch syndrome, they should consider gynecologic screenings and regular check-ups 
(6).   
 Estrogen and progesterone are known to be responsible for endometrial cell 
proliferation. Due to the conversion of androstenedione to estrone and the aromatization of 
androgens to estradiol in peripheral adipose tissue, obese women have higher levels of 
endogenous estrogen than those at a healthy weight (8). Risk for endometrial cancer has 
been correlated with these high serum estrogen levels. Therefore, obesity is one of the 
biggest risk factors for endometrial cancer development. An estimated 90% of type 1 EC 
patients are obese. Additionally, many EC patients typically develop obesity-driven co-
morbidities, such as type II diabetes, hypertension, and pulmonary disease (8). It is 
extremely important to initiate corrective interventions such as diet, exercise or even 
bariatric surgery. If weight loss is difficult, patients should also consider hormonal 
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interventions, such as oral contraceptive pills, in order to regulate menstrual cycles to help 
prevent endometrial hyperplasia or cancer.  
 Not all at-risk women will develop EC. Identification of molecular changes that 
distinguish normal endometrium from endometrial cancer could potentially aid in 
identifying at-risk women who are especially prone to develop endometrial cancer. 
Therefore, it is especially important to identify tissue biomarkers that will help to indicate an 
individual woman’s predisposition to EC.  
 
Microarray Analysis 
 A microarray analysis was performed using normal proliferative-phase endometrium 
from thin and obese women and cancerous endometrium from obese women. This array 
provided 22 candidate genes that could help distinguish obese normal endometrium from 
obese endometrial cancers. Of the 22 candidate genes, ten genes that had not been 
previously studied in depth in endometrial cancer were chosen for validation using 
quantitative real time polymerase chain reaction (qRT-PCR). Some background on these 
genes is provided below.  
 
Placental Cadherin (P-Cadherin) 
 Placental cadherin (P-cadherin) is part of the classical cadherin family, which are 
calcium dependent cell adhesion proteins that contribute to embryogenesis, homeostasis of 
normal epithelia and tumorigenesis (9). P-cadherin is found in the basal layers of stratified 
epithelia, suggesting that it functions in cell differentiation and growth (10).  
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Van Marck et al. (9) examined the specific function of P-cadherin in colon and 
bladder carcinomas through immunohistochemistry. They determined that a decrease or loss 
of membranous P-cadherin expression significantly correlated with a higher tumor grade and 
could distinguish well differentiated tumors from moderately or poorly differentiated 
colorectal cancers. Their results suggested that P-cadherin has anti-invasive and anti-
migratory functions (9).  
As P-cadherin could have a prognostic significance, Stefannson et al. (10) 
investigated the expression patterns of cellular adhesion markers, including E-cadherin, P-
cadherin, and β-catenin, in a series of endometrial carcinomas. They collected tumor tissues 
from 286 patients and recorded histologic characteristics such as histotype, FIGO grade, 
solid growth, necrosis, myometrial infiltration, and growth pattern.  
Increased P-cadherin expression was seen in 83 of the patients, with a significantly 
higher amount of clear cell or serous papillary type. Increased P-cadherin expression also 
correlated with vascular invasion, deep myometrial invasion, and increasing FIGO stage. 
Specifically among the endometrioid tumors, high P-cadherin expression correlated with 
increasing FIGO grade and deep myometrial invasion. This group’s findings imply that P-
cadherin up-regulation is important for distinction between endometrioid and non-
endometrioid tumors (10). 
 
OLFM1 (Noelin-1)  
OLFM1, also called Noelin-1, encodes a secreted glycoprotein belonging to a family 
of olfatomedin domain containing proteins. It functions in regulating the production of 
neural crest cells by the neural tube and is down-regulated in endometrial cancer, Ewing’s 
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sarcoma, and neuroblastoma (11). In a study performed by Wu et al. (11), strong 
cytoplasmic staining of OLFM1 was seen in patients with non- small cell lung cancer, 
especially in adenocarcinomas compared to normal lung tissues. However, they did not find 
a difference in expression of OLFM1 in adenocarcinomas at early stage and late stage.   
Wong et al. (12) recently used gene expression profiling to identify potential 
molecular markers in endometrial cancer. Genome-wide expression profiles were 
determined for 84 endometrioid endometrial tumors and normal samples. Their initial 
microarray found OLFM1 to be one of the genes down-regulated in endometrial cancers 
compared to normal endometrium. Further qRT-PCR was performed on a different set of 56 
cancer and 29 normal samples. The change in expression seen by qRT-PCR was comparable 
to the initial microarray results. Their findings identified potential clinical markers for 
endometrioid endometrial cancers (12).  
 
VAV3 
VAV3 encodes a quinine nucleotide exchange factor (GEF) for Rho family GTPases, 
and it is part of the Vav family proteins, of which there are three. The levels of each of the 
three proteins vary depending on the tissue examined; hematopoietic cells mainly express 
VAV1 while VAV2 and VAV3 are ubiquitously expressed. Activation of Vav proteins 
occurs through tyrosine phosphorylation by receptor protein tyrosine kinases or cytoplasmic 
protein tyrosine kinases (13).  
In breast cancer, VAV3 binds to estrogen receptor alpha (ERα), enhancing its 
activity through the PI3K-AKT signaling pathway. This potentiates epithelial growth factor 
(EGF) for cell growth and ERα activation. Lee et al. (13) detected VAV3 staining in 67% of 
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the well to moderately differentiated breast cancer samples analyzed and 100% of the poorly 
differentiated breast cancer samples analyzed. Additionally, decreased VAV3 expression 
significantly inhibits both estrogen independent and estrogen dependent growth in breast 
cancer cells (13). Overall, they determined that VAV3 overexpression increases ERα-
mediated signaling and contributes to the progression of breast cancer (13).  
 
Sprouty1 (SPRY1) 
Sprouty proteins were first discovered as negative regulators of fibroblast growth 
factor (FGF) signaling during tracheal and eye development in Drosophila (14). They were 
later established as inhibitors of growth factor induced receptor tyrosine kinase (RTK) 
signaling pathways that take part in Drosophila development. Drosophila has only one Spry 
gene while humans and mice have at least four Spry homologs, Spry1-4 (15). 
Mammalian Sprouty proteins block growth factor induced cell responses through 
inhibiting the RTK dependent RAS/mitogen activated protein kinase signaling pathways. 
Many mechanisms have been proposed for Spry inhibition of this pathway, such as 
inhibition of Raf (15). This pathway plays a role in tissue remodeling. SPRY1 and SPRY2 are 
specifically expressed in the luminal epithelial cells of the normal breast ducts. Increased 
expression is seen during tissue remodeling as the epithelial ducts are branching. SPRY1 and 
SPRY2 are consistently down-regulated in breast cancers. This suggests Sprouty proteins act 
as regulators of epithelial cell growth (16). 
In prostate cancer, the Spry1 homolog is down-regulated in prostate cancer tissues 
compared to normal prostate tissue, as measured by qRT-PCR. In addition, an increased 
expression of SPRY1 inhibits prostate cancer cell proliferation (15).  
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PIK3R1 
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that have significant regulatory 
roles in cell survival, differentiation, and proliferation. Depending on their substrate 
characteristics and substrate specificity, they are separated into three classes. The Class I 
enzymes are more commonly known; they are subcategorized into Class IA PI3Ks and Class 
IB PI3Ks. Class IA PI3Ks are activated by G-protein coupled receptors (GPCRs), receptor 
tyrosine kinases (RTKs), and various oncogenes, such as RAS while GPCRs are the sole 
regulator of Class IB enzymes. Class IA PI3Ks are heterodimers consisting of a p85 
regulatory subunit and a p110 catalytic subunit. The PI3K regulatory subunit 1 (PIK3R1) 
encodes p85α. Genomic analyses of human glioblastomas found PIK3R1 to be mutated in 
10% of tumors analyzed and somatic mutations of PIK3R1 have also been seen in primary 
human ovarian and colon tumors (17).  
The PI3K pathway is mutated in several cancer lineages, including endometrial 
cancer. Mills et al. determined that PIK3R1 is frequently mutated in 20% of endometrial 
cancers, higher than any other cancer lineage which suggests selective targeting in EC. Co-
mutations in other PI3K pathway members may also contribute to cell transformation. Co-
mutations in the PI3K pathway occur more frequently in EC than in other cancer types, with 
PIK3CA, PIK3R1, or PIK3R2 mutations being more common when the PTEN protein is 
retained. Additionally, Mills et al. reported haploinsufficiency of PIK3R1 can result in PI3K 
pathway activation, whereas homozygous deletion inhibits the pathway. Overall, there are 
several mechanisms through which PIK3R1 aberrations can contribute to tumorigenesis, but 
further studies are required to elucidate the effects of each mutation (18).   
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PEG3 
PEG3, which is highly conserved between mice and humans and thus likely 
contributes to critical cellular functions, has 12 Kruppel-type zinc finger DNA binding 
domains and a protein-protein interaction domain (19). PEG3 possibly acts as a transcription 
factor due to its two proline- and acidic amino acid-rich regions which have transactivation 
domains. Also, PEG3 potentially plays a role in the p53/c-myc-mediated apoptosis pathway, 
suggesting it functions in carcinogenesis. While the highest PEG3 mRNA levels have been 
found in the placenta, ovary, uterus, testis, and brain, PEG3 is expressed nearly universally 
(19). Decreased PEG3 expression levels have been observed in endometrial and ovarian 
cancer through gene expression profiling (19). Additionally, biallelic silencing of PEG3 has 
been reported in human glioma cell lines (19). 
Dowdy et al. (19) further investigated the possible tumor suppressive function of 
PEG3 in gynecologic cancers. Through qRT-PCR and methylation specific PCR, they 
detected PEG3 expression in normal ovarian, cervical, endometrial, and placental tissues, 
but they did not observe PEG3 expression in different endometrial (Ishikawa, AN3CA, 
KLE, RL95-2, HEC-1A, HEC-1B, ARK-1, ARK-2) and cervical cancer cell lines. They also 
determined PEG3 expression to be inversely correlated with promoter methylation levels, 
suggesting PEG3 expression is controlled by epigenetic mechanisms.  
 
Ephrin-A1 (EFNA1) 
The first ephrin protein Ephrin-A1, or EFNA1, was discovered in 1990 as an early 
response gene to TNF-α stimulation in human umbilical vein endothelial cells. It was later 
identified as a ligand for the EphA2 receptor. The ephrin family is composed of eight 
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members, which are further divided into A and B subgroups. Ephrin ligands are separated 
based on their method of cell membrane attachment while ephrin receptors are divided 
depending on their sequence homology. Generally, EphA receptors bind to ephrin-A ligands 
and EphB receptors bind to ephrin-B ligands (20). Expression of the ligands and receptors 
simultaneously may cause autocrine or paracrine signaling in tumor cells. It may also result 
in both forward and reverse signaling which contributes to the development and progression 
of the tumor (21).  
Altered ephrin expression has been reported in several human cancers, such as 
melanomas, carcinomas, sarcomas, and brain tumors. Some tumors have an elevated 
expression of ephrins while others show a decreased expression. Literature has shown 
ephrins to contribute to tumorigenicty, angiogenesis, metastasis, and invasion and migration 
(21). In addition, studies have reported that a higher expression of EFNA1 has been 
associated with poorer patient survival in various cancers, including ovarian cancers, 
melanomas, and vulvar carcinomas (21).  
EphA2, the receptor for EFNA1, is up-regulated in many solid tumors, including 
breast, prostate and non-small cell lung cancer. In addition, EphA2 plays a role in tumor 
angiogenesis. Merritt et al. (22) investigated EphA2 in endometrial cancer. Overexpression 
of EphA2 is associated with up-regulation of angiogenic markers, such as vascular epithelial 
growth factor (VEGF) and microvessel density. VEGF and microvessel density are also 
associated with high-grade, high-stage phenotypic features of endometrial cancers. Due to 
the strong correlation of EphA2 with angiogenesis, Merritt et al. (22) also investigated the 
therapeutic implications of EphA2 by using an EphA2 agonistic antibody, EA5, in uterine 
cancer models. EA5 binds to EphA2, causing it to be phosphorylated and thus, decreasing 
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EphA2 expression. Therefore, EA5, along with cytotoxic therapy, significantly reduced the 
growth of endometrial cancers (22).  
 
Endothelin receptor type A (EDNRA) 
 EDNRA, also known as endothelin receptor type A (ETAR), is a distinct subtype of 
G-protein coupled receptors, acting on endothelin-1 (ET-1). This ligand-receptor complex is 
overexpressed in primary and metastatic ovarian carcinomas. Through EDNRA, ET-1 
functions as an autocrine growth, survival, and angiogenic factor specifically in ovarian 
tumor cells. In doing so, it activates several signaling pathways such as the mitogen 
activated protein kinase (MAPK) pathway and the PI3K-Akt pathway. Rosanò et al. (23) 
have shown that through the activation of the ET-1/EDNRA pathway, ovarian cancer cells 
undergo an epithelial-to-mesenchymal transition. Additionally, EDNRA expression was 
significantly associated with a decrease in E-cadherin, which is responsible for mediating 
cell-cell interaction. Grades 3 and 4 ovarian serous and endometrioid carcinomas showed 
higher expression levels compared to early grade cancers, suggesting EDNRA expression is 
grade dependent. In addition, when ET-1/EDNRA signaling was interrupted through 
EDNRA antagonists, E-cadherin transcription levels increased and tumor growth decreased. 
This data suggest EDNRA contributes to the epithelial to mesenchymal transition (23). 
 
HEYL 
HEYL belongs to the hairy enhancer of split related family of genes and is a basic 
helix-loop-helix transcription factor. There are three related HEY proteins, HEY1, HEY2, 
and HEYL (24). HEYL can be activated through constitutive active forms of Notch 
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receptors (25). Its expression in human endothelial cells is correlated with increased cell 
growth and anti-apoptosis activity (25). In breast cancer, Parker et al. (25) have found it to 
be overexpressed. A HEYL mixture probe was used to test for the expression of HEYL in 
normal tissue and invasive ductal carcinomas. They did not find any staining in the normal 
tissues, but there was a strong labeling of the HEYL probes in invasive ductal carcinomas. 
Their study showed a dramatic induction in breast tumor vasculature by at least 10 fold 
relative to normal breast vasculature. Additionally, they found a ≥10-fold increase in breast 
tumor endothelial cells. Specifically, in invasive breast cancer, HEYL expression was 
predominantly seen in breast endothelial cells with minimal expression in tumor epithelial 
cells (25).  
 
HES1 
 HES1 is part of the Hes family, which also belongs to the basic helix-loop-helix 
family of transcription factors. HES1 is one of the target genes of the Notch signaling 
pathway, which is involved in many different cancers (26).   
Zhang et al. (26) investigated the role of Notch and HES1 in osteosarcoma invasion 
and metastasis. They used RT-PCR to analyze human osteosarcoma cell lines. They 
determined that Notch and HES1 expression correlate with the metastatic phenotype in 
osteosarcoma cells. Additionally, HES1 expression has also been reported to be higher in 
ovarian carcinomas compared to benign ovarian tumors (27).   
 Gotte et al. (28) investigated the effects of Musashi-1, a stem cell marker, on 
endometrial carcinoma progression and apoptosis through the Notch signaling pathway. 
While the specific function of Musashi-1 in endometrial cancer is unknown, other studies 
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have found it to participate in tumor growth. Typically, Musashi-1 acts as positive regulator 
of Notch mediated transcription by repressing Numb proteins, which induce Notch 
internalization and intracellular degradation. Gotte et al. (28) observed the effects of 
Musashi-1 knockdown on protein expression of vital components of the Notch signaling 
pathway in the endometrial adenocarcinoma cell line, Ishikawa. Knockdown of Musashi-1 
resulted in a significant down-regulation of Notch1 and HES1 in Ishikawa cells.  
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Chapter 2 
Materials and Methods 
 
Human normal endometrial biopsies, tumor samples, and cell lines.  
 Following IRB approval (LAB01-718), frozen endometrial carcinomas (n=78) and 
benign endometrium (n=10) were obtained as residual tissues from hysterectomies 
submitted to the Department of Pathology, M.D. Anderson Cancer Center. Benign 
endometrial tissues were typically obtained from hysterectomies for cervix dysplasia/cancer 
uterine leiomyomas, or benign ovarian cysts. Characteristics of the patients whose 
specimens were used are summarized in Table 2.  
 
Table 2. Patient Characteristics.  
Normal Endometrial Samples n = 10 
Age (years)  
Mean 46.7 
Median 46 
Body Mass Index (kg/m
2
)  
Mean 27.8 
Median 27.5 
Endometrial Cancer Samples n = 78 
Age at diagnosis (years)  
Mean 62.8 
Median 63 
Body Mass Index (kg/m
2
)  
Mean 33.7 
Median 31.25 
Stage at diagnosis, n (%)  
I 48 (61.5) 
II 5 (0.06) 
III 21 (26.9) 
IV 4 (0.05) 
Histology, n (%)  
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Endometrioid 49 (62.8) 
Non-endometrioid 29 (37.2) 
Serous and Mixed
1
 15 (19.2) 
MMMT
1
 14 (17.9) 
Endometrioid grade, n (%)  
1 9 (18.4) 
2 22 (44.9) 
3 18 (36.7) 
1
Tumors with mixed endometrioid and non-endometrioid components.  
 
Surgical stage was determined using the 2010 FIGO staging system. Stage IA and IB tumors 
are confined to the uterus, with IA tumors having none or less than half myometrial invasion 
and IB tumors having more than half myometrial invasion. Stage II tumors are also confined 
to the uterus, but they invade cervical stroma. Stage IIIA tumors invade the uterine serosa, 
ovaries or fallopian tubes, and Stage IIIB tumors involve the vagina and the parametrial 
area. Stage IIIC1 tumors have pelvic lymph node involvement, and Stage IIIC2 tumors have 
para-aortic lymph node involvement. Stage IVA tumors invade the bladder and the bowel 
mucosa, while stage IVB tumors have distant metastases including abdominal metastases 
and the inguinal lymph nodes.  
 
RNA Isolation 
Total RNA was isolated from tissues using a phenol-based method. Samples were 
homogenized via a polytron in TRIzol® Reagent (Invitrogen, Carlsbad, CA) and mixed with 
chloroform. Lysates were separated into three phases by centrifugation. Total RNA was 
precipitated from the aqueous phase with isopropanol, washed with 75% DEPC-ethanol, and 
re-suspended in DEPC H2O. Isolated RNA was DNase (Epicenter Biotechnologies, 
Madison, WI) treated.  
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Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Probe-based, real-time quantitative real-time PCR (qRT-PCR) assays for P-
Cadherin, OLFM1, VAV3, SPRY1, PIK3R1, EDNRA, EFNA1, PEG3, HES1, HEYL, Notch4, 
Jagged1, and 18S rRNA were developed using Primer Express software (Applied 
Biosystems) based on sequences from Genbank. qRT-PCR was performed using a 7700 
Sequence Detector (Applied Biosystem, Foster City, CA). All qRT-PCR reactions were 
performed in the Quantitative Genomics Core Laboratory (UT-Houston Medical School, 
Houston, TX). Primer and probe sequences and accession number of assays developed and 
used in this thesis are indicated in Table 3.  
 
Table 3. Probes and primers for quantitative RT-PCR assays.  
Transcript Taqman Primers and Probe Accession Number 
P-Cadherin 1820(+) CCAGGTACTTCTGTGATG 
1879(-)GTAGGTGTAGATGGCATC 
1860(-) FAM- TCCTCATCCGTGGCTGTCA-BHQ1 
NM_001793 
OLFM1 705(+) GAGAAGGTGCAGAACATG 
773(-) GTACTGCAAGTCTCTCTG 
752(-) FAM-CCGCCTGTCCAAGACCTCTATG-BHQ1 
NM_014279 
VAV3 2320(+) AGAACCTTAGATACAACTCTG 
2401(-) TGTTGCCTGCTCTATTAC 
2348(+)FAM-CATACAAGGAGCCAGAACATTCAGC-
BHQ1 
NM_006113 
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SPRY1 995(+) GTCAAGGGCATCTTCTAC 
1068(-) GAACAGGAGCAAGGATTA 
1015(+) FAM-CTGCTCCAATGACGACGAAGG-BHQ1 
NM_005841 
PIK3R1 2710(+) CAATGTCACACTAGCCTA 
2782(-) CAGGAGAAGGATCAAAGA 
1756(-) FAM-TTCATCGCCTCTGCTGTGCBHQ1 
NM_181523 
HES1 417(+) CTGATTTTGGATGCTCTG 
500(-) GTGCTTCACTGTCATTTC 
478(-) FAM-ATGTCCGCCTTCTCCAGC-BHQ1 
NM_005524 
EDNRA 1502(+) AAGCCGTATATTGAAGAAAAC 
1579(-) ATGAGCAGTAAGAAACTAAGTA  
1552(-)FAM-CATCGGTTCTTGTCCATCTCGTTAT_BHQ1 
NM_001957 
PEG3 3813(+) GTACACACATTCTGTAATTCA 
3897(-) CACTTTGGACATTCATACAG 
3835(-)FAM-CCATTCCATCAGCGAGTATCAGAGA-
BHQ1 
NM_006210 
HEYL 1132(+) ACTGGCTCATATGTGAAG 
1208(-) CAGTGAGAAGGAGAGATG 
1153(+) FAM-CGTTCTCCAGCCATCAGAGG-BHQ1 
NM_014571 
EFNA1 415(+) CTGTCTGAGAAGTTCCAG 
495(-)  GGAGATGTAGTAGTAGCTG 
473(-)FAM-CCTTCTTTGAACTCCTTGCCCAG-BHQ1 
NM_004428 
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Jagged1 4150(+) AACCGAATGGAGTACATC 
4239(-) GACACGACAGTTTAAAGAA 
4210(-) FAM-TCAGACTCTACCTAGCGGCG-BHQ1 
NM_000214 
Notch4 897(+) CAGAGAAAGACTCCACCT 
979(-) ACAGTTGTCTGGATTCAC 
915(+) FAM-TTCACCTCTGCCTCTGTCC-BHQ1 
NM_004557 
 
Roche PCR Array 
 A Notch-centric PCR array (Roche Molecular Systems, Branchburg, New Jersey) 
was used to screen the components of the Notch signaling pathway. A PCR array combines 
the gene expression profiling technique of a microarray and the quantitative aspect of qRT-
PCR. 5 µL of RNA isolated from 72 normal (n = 9) and endometrial carcinoma samples (n = 
63) were added to a 96-well plate. Then, 15 µL of Roche Master Mix was added to the wells 
and mixed. qRT-PCR reactions were performed to test for DLL1, DTX1, JAG1, JAG2, 
ADAM10, PSEN1, PSEN2, PSENEN, NOTCH1, NOTCH2, NOTCH3, NOTCH4, ATP5A1, 
TFRC, TBP, and YWHAZ expression. Table 4 summarizes the function of these components 
of the Notch pathway.  
 
Table 4. Function of Components in Notch Pathway.  
Genes Function in Notch Pathway 
DLL1 Ligand (Notch binding) 
DTX1 Ligand (Notch binding) 
JAG1 Ligand (Notch binding) 
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JAG2 Ligand (Notch binding) 
ADAM10 Enzyme that cleaves ligand-receptor complex 
PSEN1 Notch receptor processing 
PSEN2 Notch receptor processing 
PSENEN Notch receptor processing 
NOTCH1 Notch Receptor 
NOTCH2 Notch Receptor 
NOTCH3 Notch Receptor 
NOTCH4 Notch Receptor 
ATP5A1 Data normalization 
TFRC Data normalization 
TBP Data normalization 
YWHAZ Data normalization 
 
Statistical Analysis  
 Statistical differences were calculated using the Mann-Whitney U test and the 
ANOVA test. The Tukey test was performed for multiple comparisons. Differences were 
considered significant if p < 0.05. 
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Chapter 3 
Gene Validation Results 
 
The expression of each gene validated was analyzed according to tumor histotype, tumor 
grade and surgical stage. A complete list of comparisons is provided in Table 5.  
 
Table 5. Comparisons used to analyze gene expression.  
Grade 
Normal vs. Endometrioid 
Normal vs. Non-endometrioid 
Normal vs. Grade 1 Endometrioid 
Endometrioid vs. Non-endometrioid 
Grade 1 Endometrioid vs. Grade 3 Endometrioid 
Grade 3 Endometrioid vs. Non-endometrioid 
Grade 1 and 2 Endometrioid vs. Grade 3 Endometrioid and Non-endometrioid 
Stage 
For all tumors: Stages IA and IB vs. Stages II, III, IV 
For all tumors: Stages I and II vs. Stages III and IV 
For endometrioid tumors only: Stages IA and IB vs. Stages II, III, IV 
For endometrioid tumors only: Stages I and II vs. Stages III and IV  
 
The rationale for some of these group comparisons is provided below. 
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1. Normal vs. Grade 1 endometrioid – Grade 1 endometrioid tumors are well-
differentiated.   In the past, our laboratory has observed that for many genes and 
pathways, there is little difference between normal endometrium and grade 1 
endometrioid tumors. 
2. Endometrioid vs. non-endometrioid – Endometrioid tumors typically have a better 
patient prognosis than non-endometrioid tumors. 
3. Grade 1 endometrioid vs. Grade 3 endometrioid – This represents a comparison of 
well-differentiated endometrioid tumors (grade 1) and poorly differentiated 
endometrioid tumors (grade 3). 
4. Grade 3 endometrioid vs. non-endometrioid – Some authorities have posed the 
possibility that grade 3 endometrioid tumors are more like non-endometrioid tumors.  
It is known that a substantial subset of grade 3 tumors has p53 mutations.  Mutation 
of this gene is characteristic of the non-endometrioid carcinomas. 
5. Grades 1 and 2 endometrioid vs. grade 3 endometrioid and non-endometrioid – This 
represents a variation of the endometrioid-non-endometrioid comparison.  In this 
case, the grade 3 tumors are combined with the non-endometrioid category. 
6. Stages IA and IB vs. Stages II, III, IV – Patients with higher stage endometrioid 
tumors typically receive additional treatment (radiation treatment and/or 
chemotherapy) following surgery. 
7. Stages I and II vs. Stages III and IV – Patients with stage I or stage II tumors have 
tumor confined to the uterus.  Stages III and IV mean tumor is found outside the 
uterus. 
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P-cadherin 
 
 
Figure 1. Expression of P-cadherin in normal endometrium and in endometrial 
carcinomas. This graph compares P-cadherin expression levels in normal endometrium (n 
= 10), endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 
22), and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression of P-cadherin was decreased in carcinomas 
compared to normal, especially for the non-endometrioid carcinomas. 
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Figure 2. Expression of P-cadherin in normal endometrium (n = 10) and in 
endometrioid endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is 
lower in the endometrioid tumors overall, but this is not statistically significant (p = 0.0882).   
 
 
 
Figure 3. Expression of P-cadherin in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = 0.0037).   
 
 
 24 
 
 
Figure 4. Expression of P-cadherin in endometrioid endometrial carcinomas (grades 1, 
2, 3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Non-
endometrioid tumors have significantly lower expression (p = 0.0367). 
 
 
 
Figure 5. Expression of P-cadherin in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Normal endometrium and grade 1 tumors 
have comparable expression (p = 0.3616).  
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Figure 6. Expression of P-cadherin in grade 1 EECs (n = 9) and in grade 3 EECs (n = 
18). There is no significant difference between grade 1 and grade 3 (p = 0.3963). 
 
 
 
 
Figure 7. Expression of P-cadherin in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significantly 
different (p = 0.3516). 
 
 26 
 
 
Figure 8. Expression of P-cadherin in grades 1 and 2 EECs (n = 31) and in grade 3 
EECs and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly 
lower expression compared to the grades 1 and 2 group (p = 0.0052).  
 
 
 
Figure 9. Expression of P-cadherin in grade 1 EECs (n = 9) and in grade 3 EECs and 
NEECs (n = 47). No significant difference in expression is observed between these groups 
(p = 0.1176).  
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Figure 10. Expression of P-cadherin in normal endometrium and in endometrial 
carcinomas by FIGO stage. 
 
 
Figure 11. Expression of P-cadherin in stages IA and IB endometrial carcinomas (n = 
48) compared to combined stages II, III, and IV (n = 30). Higher stages have slightly 
lower expression, but this difference is not significant (p = 0.1575).  
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Figure 12. Expression of P-cadherin in stage I and II endometrial carcinomas and in 
stages III and IV endometrial carcinomas. Higher stages have slightly lower expression, 
but this difference is not significant (p = 0.2458). 
 
 
 
 
 
Figure 13. Expression of P-cadherin in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.2128).  
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Figure 14. Expression of P-cadherin in stages I and II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have lower expression but this 
difference is not significant (p = 0.2985). 
 
Through immunohistochemistry, other groups have found higher P-cadherin expression in 
uterine clear cell carcinomas or serous carcinomas (10). High expression was also correlated 
with high FIGO grade, vascular invasion, and increasing FIGO stage (10). Our results are 
not in accordance with the literature. We found there to be significant decrease of P-
cadherin expression in non-endometrioid endometrial carcinomas compared to normal 
endometrium (p = 0.0037), as well as between endometrioid endometrial carcinomas and 
non-endometrioid endometrioid carcinomas (p = 0.0367).  
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OLFM1 
 
Figure 15. Expression of OLFM1 in normal endometrium and in endometrial 
carcinomas. This graph compares OLFM1 expression levels in normal endometrium (n = 
10), endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 
22), and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression of OLFM1 was significantly decreased in 
carcinomas compared to normal.  
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Figure 16. Expression of OLFM1 in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is significantly 
lower in the endometrioid tumors overall (p = <0.0001).  
 
 
 
 
 
Figure 17. Expression of OLFM1 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001).  
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Figure 18. Expression of OLFM1 in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Expression is 
lower in non-endometrioid tumors, but it is not statistically significantly (p = 0.0907).  
 
 
 
 
 
Figure 19. Expression of OLFM1 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Expression is significantly lower in grade 
1 tumors (p = 0.0088).  
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Figure 20. Expression of OLFM1 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 18). 
Expression is significantly lower in grade 3 tumors (p = 0.0379).   
 
 
 
 
Figure 21. Expression of OLFM1 in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significantly 
different (p = 0.2372). 
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Figure 22. Expression of OLFM1 in grades 1 and 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = 0.0053).  
 
 
 
 
Figure 23. Expression of OLFM1 in normal endometrium and in endometrial 
carcinomas by FIGO stage. 
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Figure 24. Expression of OLFM1 in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have slightly lower 
expression, but this difference is not significant (p = 0.1960). 
 
 
 
 
Figure 25. Expression of OLFM1 in stage I and II endometrial carcinomas and in 
stages III and IV endometrial carcinomas. Higher stages have slightly lower expression, 
but this difference is not significant (p = 0.2551). 
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Figure 26. Expression of OLFM1 in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.2622). 
 
 
 
 
 
Figure 27. Expression of OLFM1 in stages I and II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have lower expression but this 
difference is not significant (p = 0.3675).  
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Based on our results, we found OLFM1 expression to be significantly down-regulated in 
carcinomas, specifically in the higher grade endometrioid tumors and non-endometrioid 
tumors. These results are in accordance with the previously published data (12).  
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VAV3 
 
Figure 28. Expression of VAV3 in normal endometrium and in endometrial 
carcinomas. This graph compares VAV3 expression levels in normal endometrium (n = 10), 
endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 22), 
and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression of VAV3 was increased in low grade 
endometrial carcinomas compared to normal, but significantly decreased for the non-
endometrioid carcinomas. 
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Figure 29. Expression of VAV3 in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is higher in the 
endometrioid tumors overall, but this difference is not statistically significant (p = 0.2822). 
 
 
 
Figure 30. Expression of VAV3 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = 0.049). 
 
 
 40 
 
 
Figure 31. Expression of VAV3 in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Non-
endometrioid tumors have significantly lower expression (p = 0.0163).  
 
 
 
Figure 32. Expression of VAV3 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Normal endometrium and grade 1 tumors 
have comparable expression (p = 0.4313).  
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Figure 33. Expression of VAV3 in normal endometrium (n = 10) and grade 1and 2 
endometrioid endometrial carcinomas (n = 31). Normal endometrium and grades 1 and 2 
tumors have comparable expression (p = 0.1134).  
 
 
 
Figure 34. Expression of VAV3 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 18). 
There is no significant difference in expression between grade 1 and grade 3 (p = 0.4076).  
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Figure 35. . Expression of VAV3 in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significant (p = 
0.3237).  
 
 
 
 
 
Figure 36. Expression of VAV3 in grades 1 and 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = 0.0003).  
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Figure 37. Expression of VAV3 in normal endometrium and in endometrial carcinomas 
by FIGO stage. 
 
 
 
Figure 38. Expression of VAV3 in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have slightly lower 
expression, but this difference is not significant (p = 0.1000). 
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Figure 39. Expression of VAV3 in stage I and II endometrial carcinomas and in stages 
III and IV endometrial carcinomas. Higher stages have significantly lower expression (p 
= 0.0389).  
 
 
 
Figure 40. Expression of VAV3 in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.2443).  
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Figure 41. Expression of VAV3 in stages I and II endometrioid endometrial carcinomas 
compared to higher stages. Higher stages have lower expression but this difference is not 
significant (p = 0.2443).  
 
Our data showed VAV3 to be significantly down-regulated in non-endometrioid carcinomas 
compared to endometrioid carcinomas. Literature has shown VAV3 to be overexpressed in 
correlation with poorly differentiated breast carcinomas through immunohistochemistry and 
western blot analysis (13). However, our results show a higher expression in well 
differentiated endometrial carcinomas.  
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SPRY1 
 
Figure 42. Expression of SPRY1 in normal endometrium and in endometrial 
carcinomas. This graph compares SPRY1 expression levels in normal endometrium (n = 
10), endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 
22), and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). SPRY1 expression was significantly decreased in 
endometrial carcinomas compared to normal.  
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Figure 43. Expression of SPRY1 in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is significantly 
lower in the endometrioid tumors overall (p = <0.0001).  
 
 
 
Figure 44. Expression of SPRY1 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001). 
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Figure 45. Expression of SPRY1 in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Endometrioid 
tumors and non-endometrioid tumors have comparable expression (p = 0.0666).  
 
 
 
Figure 46. Expression of SPRY1 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Grade 1 tumors have significantly lower 
expression (p = 0.0055).  
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Figure 47. Expression of SPRY1 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 18). 
Grade 3 tumors have significantly lower expression (p = 0.0049).  
 
 
 
 
 
Figure 48. Expression of SPRY1 in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significantly 
different (p = 0.1993).  
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Figure 49. Expression of SPRY1 in grades 1 and 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = 0.0053).  
 
 
 
 
Figure 50. Expression of SPRY1 in normal endometrium and in endometrial 
carcinomas by FIGO stage. 
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Figure 51. Expression of SPRY1 in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have significantly 
lower expression (p = 0.0126). 
 
 
 
 
Figure 52. Expression of SPRY1 in stage I and II endometrial carcinomas and in stages 
III and IV endometrial carcinomas. Higher stages have significantly lower expression (p 
= 0.0322).  
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Figure 53. Expression of SPRY1 in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. Higher stages have significantly lower 
expression (p = 0.0371).  
 
 
 
 
Figure 54. Expression of SPRY1 in stages I and II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have lower expression but this 
difference is not significant (p = 0.0704).  
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Our results found SPRY1 expression to be significantly different when comparing several 
endometrial tumor subtypes. SPRY1 expression is significantly down-regulated in 
correlation with increasing FIGO grade (p = <0.0001). SPRY1 expression is significantly 
lower in grade 1 endometrioid endometrial carcinomas compared to normal endometrium. 
While SPRY1 expression level have not been previously studied in endometrial carcinomas, 
this gene has also been found to be down-regulated in other cancers, such as prostate and 
breast (15, 16).    
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PIK3R1 
 
Figure 55. Expression of PIK3R1 in normal endometrium and in endometrial 
carcinomas. This graph compares PIK3R1 expression levels in normal endometrium (n = 
10), endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 
22), and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression is significantly lower in endometrial 
carcinomas compared to normal.  
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Figure 56. Expression of PIK3R1 in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is significantly 
lower in the endometrioid tumors overall (p = <0.0001).  
 
 
 
 
Figure 57. Expression of PIK3R1 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001).  
 
 
 56 
 
 
Figure 58. Expression of PIK3R1 in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Non-
endometrioid tumors have significantly lower expression (p = 0.0200). 
 
 
 
 
Figure 59. Expression of PIK3R1 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Normal endometrium and grade 1 tumors 
have comparable expression (p = 0.1073).  
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Figure 60. . Expression of PIK3R1 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 
18). Grade 3 tumors have significantly lower expression (p = 0.0057).  
 
 
 
 
Figure 61. Expression of PIK3R1 in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significantly 
different (p = 0.2599).  
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Figure 62. Expression of PIK3R1 in grades 1 and 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = 0.0005).  
 
 
 
Figure 63. Expression of PIK3R1 in normal endometrium and in endometrial 
carcinomas by FIGO stage.   
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Figure 64. Expression of PIK3R1 in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have slightly lower 
expression, but this difference is not significant (p = 0.0692). 
 
 
 
 
Figure 65. Expression of PIK3R1 in stage I and II endometrial carcinomas and in 
stages III and IV endometrial carcinomas. Higher stages have slightly lower expression, 
but this difference is not significant (p = 0.0936).  
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Figure 66. Expression of PIK3R1 in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.1650). 
 
 
 
 
Figure 67. Expression of PIK3R1 in stages I and II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have lower expression but this 
difference is not significant (p = 0.1755).  
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We found PIK3R1 gene expression to be significantly down-regulated in non-endometrioid 
carcinomas compared to endometrioid carcinomas. While advanced stage tumors tend to 
have lower expression, these differences are not statistically significant when comparing to 
early stages.   
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PEG3 
 
Figure 68. Expression of PEG3 in normal endometrium and in endometrial 
carcinomas. This graph compares PEG3 expression levels in normal endometrium (n = 10), 
endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 22), 
and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression was significantly decreased in endometrial 
carcinomas compared to normal.   
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Figure 69. Expression of PEG3 in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is significantly 
lower in the endometrioid tumors overall (p = <0.0001).  
 
 
 
Figure 70. Expression of PEG3 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001).  
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Figure 71. Expression of PEG3 in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Endometrioid 
and non-endometrioid tumors have comparable expression (p = 0.2108).  
 
 
 
Figure 72. Expression of PEG3 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Grade 1 tumors have significantly lower 
expression (p = 0.0030).  
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Figure 73. Expression of PEG3 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 18). 
Grade 3 tumors have significantly lower expression (p = 0.0335).  
 
 
 
Figure 74. Expression of PEG3 in grade 3 EEC samples (n = 18) and in NEEC samples 
(n = 29). Expression in grade 3 and non-endometrioid tumors is not significantly different (p 
= 0.2702).  
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Figure 75. Expression of PEG3 in grades 1 and 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = 0.0203).  
 
 
 
Figure 76. Expression of PEG3 in normal endometrium and in endometrial carcinomas 
by FIGO stage. 
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Figure 77. Expression of PEG3 in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have slightly lower 
expression, but this difference is not significant (p = 0.1930). 
 
 
 
Figure 78. Expression of PEG3 in stage I and II endometrial carcinomas and in stages 
III and IV endometrial carcinomas. Higher stages have slightly lower expression, but this 
difference is not significant (p = 0.1533).  
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Figure 79. Expression of PEG3 in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.3020).  
 
 
 
Figure 80. Expression of PEG3 in stages I and II endometrioid endometrial carcinomas 
compared to higher stages. Higher stages have lower expression but this difference is not 
significant (p = 0.3486).  
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PEG3 gene expression was significantly lower in endometrial carcinomas compared to 
normal endometrium. PEG3 expression levels decreased in correlation with increasing 
FIGO grade (p = <0.0001). Our results are in accordance with literature, with others finding 
PEG3 expression to be present in normal endometrial tissues, but no expression in 
endometrial cancer cell lines (19). This suggests PEG3 acts as a tumor suppressor gene in 
endometrial cancers.  
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EFNA1 
 
Figure 81. Expression of EFNA1 in normal endometrium and in endometrial 
carcinomas. This graph compares EFNA1 expression levels in normal endometrium (n = 
10), endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 
22), and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression of EFNA1 was decreased in carcinomas 
compared to normal, especially for the non-endometrioid carcinomas. 
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Figure 82. Expression of EFNA1 in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is lower in the 
endometrioid tumors overall (p = 0.0072).  
 
 
 
Figure 83. Expression of EFNA1 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001).  
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Figure 84. Expression of EFNA1 in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Non-
endometrioid tumors have significantly lower expression (p = 0.0133).  
 
 
 
Figure 85. Expression of EFNA1 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Grade 1 tumors have significantly lower 
expression (p = 0.0315).  
 
 
 73 
 
 
Figure 86. Expression of EFNA1 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 18). 
Grade 3 tumors have significantly lower expression (p = 0.0031).  
 
 
 
Figure 87. Expression of EFNA1in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is comparable (p = 
0.3486).  
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Figure 88. Expression of EFNA1 in grades 1 and 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = <0.0001).  
 
 
 
Figure 89. Expression of EFNA1 in normal endometrium and in endometrial 
carcinomas by FIGO stage. 
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Figure 90. Expression of EFNA1 in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have significantly 
lower expression (p = 0.0345). 
 
 
 
Figure 91. Expression of EFNA1 in stage I and II endometrial carcinomas and in stages 
III and IV endometrial carcinomas. Higher stages have slightly lower expression, but this 
difference is not significant (p = 0.0638). 
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Figure 92. Expression of EFNA1 in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.0727).  
 
 
 
 
Figure 93. Expression of EFNA1 in stages I and II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have lower expression but this 
difference is not significant (p = 0.0842).  
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Our results demonstrated EFNA1 expression to be significantly down-regulated in 
endometrioid and non-endometrioid carcinomas compared to normal endometrium. EFNA1 
expression has not been studied in endometrial cancers but it has been shown through qRT-
PCR and immunohistochemistry to have an increase in expression in ovarian cancers, vulvar 
carcinomas, and melanomas (21). We found the opposite, suggesting EFNA1 may have a 
tumor suppressive role in endometrial cancers.  
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EDNRA 
 
Figure 94. Expression of EDNRA in normal endometrium and in endometrial 
carcinomas. This graph compares EDNRA expression levels in normal endometrium (n = 
10), endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 
22), and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression was significantly lower decreased in 
endometrial carcinomas compared to normal.  
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Figure 95. Expression of EDNRA in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is significantly 
lower in the endometrioid tumors overall (p = <0.0001).  
 
 
 
 
Figure 96. Expression of EDNRA in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001).  
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Figure 97. Expression of EDNRA in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Endometrioid 
and non-endometrioid tumors have comparable expression (p = 0.2655).  
 
 
 
Figure 98. Expression of EDNRA in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Grade 1 tumors have significantly lower 
expression (p = 0.0020).  
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Figure 99. Expression of EDNRA in grade 1 EECs (n = 9) and in grade 3 EECs (n = 
18). Grade 3 tumors have significantly lower expression (p = 0.0004).  
 
 
 
Figure 100. Expression of EDNRA in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression is slightly higher in non-endometrioid tumors (p = 0.0462).  
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Figure 101. Expression of EDNRA in grades 1 and 2 EECs (n = 31) and in grade 3 
EECs and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly 
lower expression compared to the grades 1 and 2 group (p = 0.002).  
 
 
 
Figure 102. Expression of EDNRA in normal endometrium and in endometrial 
carcinomas by FIGO stage. 
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Figure 103. Expression of EDNRA in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have significantly 
lower expression (p = 0.0392). 
 
 
 
Figure 104. Expression of EDNRA in stage I and II endometrial carcinomas and in 
stages III and IV endometrial carcinomas. Higher stages have slightly lower expression, 
but this difference is not significant (p = 0.0700). 
 84 
 
 
Figure 105. Expression of EDNRA in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.1103). 
 
 
 
Figure 106. Expression of EDNRA in stages I and II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have lower expression but this 
difference is not significant (p = 0.1814).  
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There was a strong down-regulation of EDNRA expression in both endometrioid and non-
endometrioid carcinomas compared to normal endometrial tissues. This gene has not been 
previously studied in endometrial cancers, but it has been found to have higher expression 
levels through immunohistochemistry in grades 3 and 4 ovarian serous and endometrioid 
carcinomas compared to low grade ovarian carcinomas (23), with 52% of high grade ovarian 
cancers showing positive staining for EDNRA.  
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HEYL 
 
Figure 107. Expression of HEYL in normal endometrium and in endometrial 
carcinomas. This graph compares HEYL expression levels in normal endometrium (n = 10), 
endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 22), 
and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression was significantly decreased in endometrial 
carcinomas compared to normal.  
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Figure 108. Expression of HEYL in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is significantly 
lower in the endometrioid tumors overall (p = <0.0001).  
 
 
 
Figure 109. Expression of HEYL in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001). 
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Figure 110. Expression of HEYL in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Endometrioid 
and non-endometrioid tumors have comparable expression (p = 0.1940).  
 
 
 
Figure 111. Expression of HEYL in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Grade 1 tumors have significantly lower 
expression (p = 0.0122).  
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Figure 112. Expression of HEYL in grade 1 EECs (n = 9) and in grade 3 EECs (n = 18). 
Grade 3 tumors have significantly lower expression than grade 1 tumors (p = 0.0397).  
 
 
 
Figure 113. Expression of HEYL in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significant (p = 
0.2551).  
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Figure 114. Expression of HEYL in grades 1 and 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = 0.0311).  
 
 
 
Figure 115. Expression of HEYL in normal endometrium and in endometrial 
carcinomas by FIGO stage. 
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Figure 116. Expression of HEYL in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have slightly lower 
expression, but this difference is not significant (p = 0.1831). 
 
 
 
Figure 117. Expression of HEYL in stage I and II endometrial carcinomas and in stages 
III and IV endometrial carcinomas. Higher stages have slightly lower expression, but this 
difference is not significant (p = 0.2535).  
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Figure 118. Expression of HEYL in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.3269).  
 
 
 
Figure 119. Expression of HEYL in stages I and II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have lower expression but this 
difference is not significant (p = 0.4558).  
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Our results showed HEYL expression to be significantly lower in grade 1 endometrioid 
endometrial carcinomas compared to normal endometrium (p = 0.0122). Expression levels 
decrease in accordance with increasing grade (p = <0.0001). The opposite has been observed 
in other cancers. For examples, HEYL expression has been found to be overexpressed in the 
more clinically invasive breast cancers.  Parker et al. (25) used a HEYL mixture probe to test 
for HEYL expression in normal breast tissues and in invasive ductal carcinomas. They did 
not find any staining in the normal tissues, but there was a strong labeling of the HEYL 
probes in invasive ductal carcinomas. 
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HES1 
 
Figure 120. Expression of HES1 in normal endometrium and in endometrial 
carcinomas. This graph compares HES1 expression levels in normal endometrium (n = 10), 
endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 22), 
and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression is significantly decreased in endometrial 
carcinomas compared to normal. 
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Figure 121. Expression of HES1 in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is significantly 
lower in the endometrioid tumors overall (p = <0.0001). 
 
 
 
Figure 122. Expression of HES1 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001). 
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Figure 123. Expression of HES1 in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Non-
endometrioid tumors have significantly lower expression (p = 0.0247). 
 
 
 
Figure 124. Expression of HES1 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Expression is significantly lower in grade 
1 tumors (p = 0.0435). 
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Figure 125. Expression of HES1 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 18). 
Grade 3 tumors have significantly lower expression (p = 0.0030).  
 
 
 
 
Figure 126. Expression of HES1 in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significant (p = 
0.3364). 
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Figure 127. Expression of HES1 in grades 1 and 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = <0.0001).  
 
 
 
Figure 128. Expression of HES1 in normal endometrium and in endometrial 
carcinomas by FIGO stage. 
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Figure 129. Expression of HES1 in stages IA and IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have significantly 
lower expression (p = 0.0039). 
 
 
 
Figure 130. Expression of HES1 in stage I and II endometrial carcinomas and in stages 
III and IV endometrial carcinomas. Higher stages have significantly lower expression (p 
= 0.0081).  
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Figure 131. Expression of HES1 in stages IA and IB endometrioid endometrial 
carcinomas compared to higher stages combined. Higher stages have significantly lower 
expression (p = 0.0130).  
 
 
 
Figure 132. Expression of HES1 in stages I and II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have significantly lower expression 
(p = 0.0260).  
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Similar to HEYL, HES1 expression was significantly higher in normal endometrial tissues 
compared to grade 1 endometrioid carcinomas. In ovarian cancers, HES1 is overexpressed. 
Hopfer et al. (27) studied HES1 expression levels in ovarian epithelial adenocarcinomas, 
ovarian adenomas, and epithelial ovarian cancers of low malignant potential, as well as 
human ovarian adenocarcinoma cell lines. Through qRT-PCR and Western blot analysis, 
HES1 expression was found to be higher in the malignant tumors compared to the benign 
tumors. Expression was intermediate in 11 out of 19 invasive adenocarcinomas and strong in 
7 out of 19 invasive adenocarcinomas. (27) 
 
 
Table 6 provides a summary of which genes in this panel may play a role in important 
clinical/pathological distinctions for endometrial carcinoma. Note that many of the genes 
might be potentially useful in distinguishing normal endometrium from grade 1 
endometrioid carcinomas. This may be helpful in clinical cancer prevention trials. 
Additionally, expression of many of the genes is significantly lower in grade 3 endometrioid 
carcinomas compared to grade 1 endometrioid carcinomas. Grade 3 endometrioid tumors are 
more often clinically aggressive. Interestingly, only one gene in this panel (HES1) has 
potential utility in predicting stage. This suggests that strategies to identify endometrial 
cancer biomarkers that rely on identifying normal vs. cancer differences may not be 
appropriate for finding endometrial cancer biomarkers predictive of stage.  
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Table 6. Summary of Gene Validation Results
1
.  
 Normal vs. 
Grade 1 
Endometrioid 
Endometrioid 
vs. Non-
endometrioid 
Grade 1 
Endometrioid vs. 
Grade 3 
Endometrioid 
Stages I and II vs. 
Stages III and IV 
(Endometrioid 
tumors) 
P-cadherin  X   
OLFM1 X  X  
VAV3  X   
SPRY1 X  X  
PIK3R1  X X  
PEG3 X  X  
EFNA1 X X X  
EDNRA X  X  
HEYL X  X  
HES1 X X X X 
1
The X indicates scenarios in which a specific gene may be useful in discriminating one 
group from another.  
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Chapter 4 
Notch Pathway Introduction 
 
From Chapter 3, two of the genes analyzed, HEYL and HES1, are known 
downstream target genes of the Notch signaling pathway. Both of these genes were 
significantly down-regulated in endometrial carcinomas (endometrioid and non-
endometrioid histotypes) compared to normal endometrium. Therefore, we were interested 
in probing the Notch pathway in more detail.  
The Notch signaling pathway significantly contributes to the pathogenesis of various 
cancers. Depending on the cell type, it can have a tumor suppressive role, as well as an 
oncogenic/growth promoting role (29, 30, 31). The Notch pathway is comprised of many 
components, including ligands, receptors, transcription factors, and target genes (29, 30, 31). 
Figure 133 is a schematic of this pathway, which is described in detail below.  
There are five Notch ligands, Delta-like ligand (Dll) 1, 3, 4, and Jagged (JAG) 1 and 
2. They are single transmembrane proteins containing an extracellular Delta-Serrate-Lag-2 
(DSL) domain that mediates receptor binding, and multiple EGF-like repeats. Jagged ligands 
have an extra cysteine-rich domain which Delta like ligands do not have. There are four 
Notch receptors, Notch 1-4. These receptors are single protein precursors that are cleaved 
during their transport to the cell surface by a furin-like protease. The receptors are 
heterodimers which contain an extracellular domain and an intracellular domain. (29, 30)  
All four Notch receptors use the same general signaling pathway, which is activated 
by binding of one of the Notch ligands to the extracellular domain of a Notch receptor. The 
ligand-receptor complex then undergoes several proteolytic cleavages. The first cleavage is 
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facilitated by the ADAM/TACE family of proteases and produces NEXT (notch 
extracellular truncation). NEXT is then cleaved by the γ-secretase complex, which consists 
of two proteins, presenilin and nicastrin (29). This cleavage is a critical step as it releases the 
intracellular domain of Notch, NICD. NICD subsequently translocates into the nucleus and 
binds to CSL, a constitutive transcriptional repressor. Upon Notch binding, CSL becomes a 
transcriptional activator and along with other co-factors, such as mastermind-like (MAML) 
proteins, induces transcription of downstream Notch target genes. There are several 
downstream targets of the Notch pathway, including the Hairy/Enhacer of Split related 
genes, Hes and Hey. (29, 30)  
Hes and Hey proteins contain two domains, a basic domain and a helix-loop-helix 
domain. The DNA binding specificity is determined by the basic domain, while the helix-
loop-helix domain allows for the formation of homodimers or heterodimers. Through 
interacting with the co-repressors or by blocking the transcriptional activators, both Hes and 
Hey proteins regulate gene transcription. These genes include transcription factors, c-Myc 
and NF-Kb2, cell cycle regulators, p21 and cyclin D1, growth factor receptors, such as 
HER2, and regulators of angiogenesis and apoptosis. (29) 
 
Hypothesis 
The Notch pathway acts as a tumor suppressor in the endometrium, with higher expression 
of pathway members in normal endometrium but decreased expression in endometrial 
cancer.  
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Specific Aims  
1. Examine the qRT-PCR expression of Notch pathway members, including HES1, 
HEYL, Notch4, and Jagged1, in normal endometrium and various types of 
endometrial carcinoma.  
2. Correlate Notch pathway gene expression with relevant clinical and pathological 
features of endometrial carcinoma, such as FIGO grade, stage of the tumor, and 
endometrioid and non-endometrioid histotype. 
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Figure 133. Notch Signaling Pathway. Notch ligands bind to the extracellular domain of 
the Notch receptors, causing the ligand-receptor complex to be activated and undergo 
several proteolytic cleavages. The activated form of Notch, Notch Intra-Cellular Domain 
(ICN) translocates to the nucleus, binds with transcription factors, and induces transcription 
of Notch target genes. ICN: Intra-cellular Notch; CoA: co-activators; GSI: γ-secretase 
inhibitor 
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Chapter 5 
Notch Pathway Results 
 
In order to determine which of the Notch pathway components play a significant role 
in the endometrium, we designed a Roche Notch-centric PCR array. See Chapter 2, Table 4, 
page 19 for a summary of the Notch pathway components that were represented on this 
array. PCR arrays combine the gene expression profiling feature of microarrays and the 
quantitative nature of real-time PCR. Additionally, PCR arrays can focus on a specific 
pathway, profiling the expression of all genes relevant to that pathway. 
 Using a subset of normal (n = 9) and endometrial cancer (n = 63) samples, we used 
the Notch-centric PCR array to analyze gene expression levels in four relevant categories: 
normal endometrium versus grade 1 EECs, normal endometrium versus grade 2 EECs, 
normal endometrium versus grade 3 EECs, and normal endometrium versus NEECs. Tables 
7-10 summarize the results of these analyses. Of all the Notch components analyzed, Notch4 
and Jagged1 consistently showed a significant difference in expression when comparing 
normal endometrium to the various grades of endometrial carcinomas represented in the 
array. As a result, we designed and performed qRT-PCR assays specifically for Notch4 and 
Jagged1 and examined their expression in the full set of normal endometrial tissues and 
endometrial carcinomas (figures 134-159).  
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Table 7. Roche Notch-centric PCR Array Gene Expression Levels: Normal 
Endometrium vs. Grade 1 EECs. 
 
Gene Fold Change Difference (log scale) p-value 
Notch1 -1.093 -0.128 0.725 
Notch2 -1.409 -0.495 0.234 
Notch3 1.264 0.338 0.246 
Notch4 -2.696 -1.431 0.031 
Jag1 -1.124 -0.169 0.720 
Jag2 1.167 0.223 0.707 
DLL1 -2.086 -1.061 0.100 
DTX1 -1.625 -0.701 0.574 
ADAM10 -1.212 -0.278 0.341 
PSEN1 -1.174 -0.231 0.360 
PSEN2 1.120 0.164 0.680 
PSENEN 1.556 0.638 0.112 
TFRC 1.443 0.529 0.203 
TBP -1.356 -0.440 0.240 
 
 
 
 
 
 109 
 
Table 8. Roche Notch-centric PCR Array Gene Expression Levels: Normal 
Endometrium vs. Grade 2 EECs. 
 
Gene Fold Change Difference (log scale) p-value 
Notch1 1.139 0.188 0.727 
Notch2 -1.163 -0.218 0.450 
Notch3 1.209 0.273 0.569 
Notch4 -2.728 -1.448 0.031 
Jag1 -1.710 -0.774 0.031 
Jag2 1.407 0.493 0.508 
DLL1 -2.101 -1.071 0.110 
DTX1 -1.451 -0.537 0.514 
ADAM10 1.356 0.439 0.146 
PSEN1 1.115 0.158 0.644 
PSEN2 1.393 0.479 0.353 
PSENEN -1.001 -0.001 >0.99 
TFRC 1.768 0.823 0.001 
TBP 1.182 0.241 0.533 
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Table 9. Roche Notch-centric PCR Array Gene Expression Levels: Normal 
Endometrium vs. Grade 3 EECs. 
 
Gene Fold Change Difference (log scale) p-value 
Notch1 -2.554 -1.353 0.007 
Notch2 -2.144 -1.100 0.009 
Notch3 -1.377 -0.461 0.306 
Notch4 -3.040 -1.604 0.004 
Jag1 -2.936 -1.554 0.0003 
Jag2 1.492 0.577 0.242 
DLL1 -2.387 -1.255 0.027 
DTX1 -3.111 -1.637 0.062 
ADAM10 -1.480 -0.565 0.137 
PSEN1 -1.381 -0.465 0.116 
PSEN2 1.102 0.141 0.765 
PSENEN -1.695 -0.761 0.105 
TFRC 1.526 0.610 0.020 
TBP -1.743 -0.801 0.086 
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Table 10. Roche Notch-centric PCR Array Gene Expression Levels: Normal 
Endometrium vs. Non-Endometrioid Carcinomas. 
 
Gene Fold Change Difference (log scale) p-value 
Notch1 -2.020 -1.015 0.114 
Notch2 -1.059 -0.082 0.871 
Notch3 1.108 0.148 0.676 
Notch4 -2.638 -1.400 0.035 
Jag1 -4.026 -2.009 0.002 
Jag2 1.446 0.532 0.257 
DLL1 -2.156 -1.109 0.049 
DTX1 -1.979 -0.985 0.213 
ADAM10 -1.865 -0.899 0.053 
PSEN1 -1.504 -0.589 0.095 
PSEN2 1.104 0.143 0.803 
PSENEN -1.285 -0.361 0.288 
TFRC 1.261 0.335 0.440 
TBP -1.052 -0.073 0.862 
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Notch4  
 
Figure 134. Expression of Notch4 in normal endometrium and in endometrial 
carcinomas. This graph compares Notch4 expression levels in normal endometrium (n = 
10), endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 
22), and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression of Notch4 was decreased in endometrial 
carcinomas compared to normal.  
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Figure 135. Expression of Notch4 in normal endometrium (n = 10) and in endometrioid 
endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is significantly 
lower in the endometrioid tumors overall (p = <0.0001).  
 
 
 
Figure 136. Expression of Notch4 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001).  
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Figure 137. Expression of Notch4 in endometrioid endometrial carcinomas (grades 1, 2, 
3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Non-
endometrioid tumors have significantly lower expression (p = 0.0228).  
 
 
 
Figure 138. Expression of Notch4 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Normal endometrium and grade 1 tumors 
have comparable expression (p = 0.2838). 
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Figure 139. Expression of Notch4 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 
18). Grade 3 have significantly lower expression than grade 1 tumors (p = 0.0023).  
 
 
 
Figure 140. Expression of Notch4 in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significant (p = 
0.1781).  
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Figure 141. Expression of Notch4 in grades 1 & 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = 0.0002).  
 
 
 
Figure 142. Expression of Notch4 in normal endometrium and in endometrial 
carcinomas by FIGO stage. 
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Figure 143. Expression of Notch4 in stages IA & IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have significantly 
lower expression (p = 0.0409). 
 
 
 
Figure 144. Expression of Notch4 in stage I & II endometrial carcinomas and in stages 
III & IV endometrial carcinomas. Higher stages have slightly lower expression, but this 
difference is not significant (p = 0.0970).  
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Figure 145. Expression of Notch4 in stages IA & IB endometrioid endometrial 
carcinomas compared to higher stages combined. No significant difference is noted (p = 
0.0901). 
 
 
 
Figure 146. Expression of Notch4 in stages I & II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have lower expression but this 
difference is not significant (p = 0.1738).  
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Our results found Notch4 expression to be significantly different when comparing several 
endometrial tumor subtypes. Notch4 expression was significantly higher in normal 
endometrial tissues compared to endometrial carcinomas (p = <0.0001). Higher expression 
was also seen in EEC samples compared to NEEC samples (p = 0.0228).  
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Jagged1 
 
Figure 147. Expression of Jagged1 in normal endometrium and in endometrial 
carcinomas. This graph compares Jagged1 expression levels in normal endometrium (n = 
10), endometrioid endometrial carcinomas (EECs), which includes grade 1 (n = 9), 2 (n = 
22), and 3 (n = 18), and non-endometrioid endometrial carcinomas (NEECs), which includes 
malignant mixed mullerian tumors (MMMT; n = 14) and serous and mixed-serous 
endometrioid carcinomas (n = 15). Expression of Jagged1 was decreased in endometrial 
carcinomas compared to normal.   
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Figure 148. Expression of Jagged1 in normal endometrium (n = 10) and in 
endometrioid endometrial carcinomas (grades 1, 2, and 3; total n = 49). Expression is 
significantly lower in the endometrioid tumors overall (p = <0.0001). 
 
 
 
Figure 149. Expression of Jagged1 in normal endometrium (n = 10) and in non-
endometrioid endometrial carcinomas (n = 29). Non-endometrioid tumors have 
significantly lower expression (p = <0.0001). 
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Figure 150. Expression of Jagged1 in endometrioid endometrial carcinomas (grades 1, 
2, 3; total n = 49) and in non-endometrioid endometrial carcinomas (n = 29). Non-
endometrioid tumors have significantly lower expression (p = 0.0087). 
 
 
 
Figure 151. Expression of Jagged1 in normal endometrium (n = 10) and in grade 1 
endometrioid endometrial carcinomas (n = 9). Normal endometrium and grade 1 tumors 
have comparable expression (p = 0.1040).  
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Figure 152. Expression of Jagged1 in grade 1 EECs (n = 9) and in grade 3 EECs (n = 
18). Grade 3 tumors have significantly lower expression compared to grade 1 tumors (p = 
0.0006). 
 
 
 
Figure 153. Expression of Jagged1 in grade 3 EEC samples (n = 18) and in NEEC 
samples (n = 29). Expression in grade 3 and non-endometrioid tumors is not significant (p = 
0.1798).  
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Figure 154. Expression of Jagged1 in grades 1 & 2 EECs (n = 31) and in grade 3 EECs 
and NEECs (n = 47). The grade 3 and non-endometrioid tumors have significantly lower 
expression compared to the grades 1 and 2 group (p = <0.0001).  
 
 
 
Figure 155. Expression of Jagged1 in normal endometrium and in endometrial 
carcinomas by FIGO stage.  
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Figure 156. Expression of Jagged1 in stages IA & IB endometrial carcinomas (n = 48) 
compared to combined stages II, III, and IV (n = 30). Higher stages have significantly 
lower expression (p = 0.0082). 
 
 
 
Figure 157. Expression of Jagged1 in stage I & II endometrial carcinomas and in stages 
III & IV endometrial carcinomas. Higher stages have significantly lower expression (p = 
0.0208).  
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Figure 158. Expression of Jagged1 in stages IA & IB endometrioid endometrial 
carcinomas compared to higher stages combined. Higher stages have significantly lower 
expression (p = 0.0415).  
 
 
 
Figure 159. Expression of Jagged1 in stages I & II endometrioid endometrial 
carcinomas compared to higher stages. Higher stages have significantly lower expression 
(p = 0.0392).  
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Our results found Jagged1 expression to be significantly different when comparing several 
endometrial tumor subtypes. Jagged1 expression was significantly higher in normal 
endometrial tissues compared to endometrial carcinomas (p = <0.0001). Jagged1 expression 
was significantly lower in poorly differentiated endometrial carcinomas compared to low 
grade, well-differentiated endometrial carcinomas.  
 
Summary  
Our results show a significant decrease in expression level of both Notch4 and 
Jagged1 in correlation with higher FIGO grade and stage. This is comparable to the 
expression levels of both target genes of the Notch signaling pathway, HEYL and HES1. 
Table 11 provides a summary of the qRT-PCR results for these four components of the 
Notch pathway. All four components were significantly down-regulated in poorly 
differentiated, clinically invasive endometrial carcinomas compared to normal endometrium 
and well-differentiated, low grade endometrial carcinomas. Based on this data, we believe 
the Notch pathway to play a tumor suppressive role in endometrial cancer.  
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Table 11. Summary of qRT-PCR Results: Notch Pathway Components.  
 Normal vs. 
Grade 1 
Endometrioid 
Endometrioid 
vs. Non-
endometrioid 
Grade 1 
Endometrioid 
vs. Grade 3 
Endometrioid 
Stages I and II vs. 
Stages III and IV 
(Endometrioid 
tumors) 
HEYL X  X  
HES1 X X X X 
Notch4  X X  
Jagged1  X X X 
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Chapter 6 
Discussion 
 
The most common gynecologic malignancy and the fourth most common cancer 
among women is endometrial carcinoma (1, 2). As with other cancer types, endometrial 
carcinoma has been the focus of numerous studies to characterize its molecular 
pathogenesis, including the large-scale efforts of The Cancer Genome Atlas. Despite these 
efforts, the molecular events affiliated with the progression of endometrial carcinoma from 
normal endometrium are still largely uncharacterized. Therefore, the identification of 
molecular markers of tumor development would have a significant clinical impact. The 
purpose of this thesis was to determine gene expression levels associated with endometrial 
cancer development and identify molecular markers that could potentially be used for 
therapeutic targeting or as biomarkers of cancer risk in high risk populations, such as obese 
women or women with Lynch Syndrome.   
Many microarray studies have been performed to identify genes that are abnormally 
expressed in endometrial tumors compared to normal endometrium (12). Based on a 
previous microarray study performed on normal endometrium from obese women and 
cancerous endometrium from thin and obese women, we validated a number of genes which 
were significantly up-regulated or down-regulated. Furthermore, two of the ten genes 
studied belong to the same signaling pathway, the Notch pathway. While the role of various 
Notch pathway members has been documented in other cancer types, their specific function 
in endometrial cancer has not been determined yet. The Notch pathway has been reported to 
function in cell differentiation, proliferation, apoptosis, as well as vascular development and 
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angiogenesis (32). Based on our observation of low expression of HEYL and HES1, target 
genes of the Notch pathway, we hypothesized this pathway to have a tumor suppressive role 
in endometrial cancer. Following validation of the initial 10 genes, this thesis then primarily 
focused on a comprehensive examination of Notch pathway components, including ligands, 
receptors, processing enzymes, and downstream indicators of pathway activation, in normal 
endometrium, endometrioid adenocarcinoma, and non-endometrioid adenocarcinoma.  
 
First 10 genes  
Several of the genes initially validated gave promising results and could be targeted 
for therapeutic implications. We compared gene expression levels according to endometrial 
cancer grade and stage and found some genes to show a dramatic difference in expression 
depending on the tumor histotype. We primarily focused on four comparisons: normal 
endometrium versus grade 1 endometrioid tumors; endometrioid tumors versus non-
endometrioid tumors; grade 1 endometrioid carcinomas versus grade 3 endometrioid 
carcinomas; and stages I and II endometrioid endometrial carcinomas versus stages III and 
IV endometrioid endometrial carcinomas. Based on the results of the qRT-PCR, we 
categorized the ten genes into one or more of these four comparison groups (see Table 6).  
OLFM1, SPRY1, PEG3, EDNRA, and HEYL had high expression levels in normal 
endometrium, but were significantly down-regulated in grade 1 endometrioid tumors. The 
low expression levels in endometrial cancer suggest that these genes may normally function 
as tumor suppressors and/or growth inhibitors that are somehow being inactivated or 
inhibited. Further studies are necessary to determine the mechanism responsible for this 
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action. Subsequently, therapies could be developed that target the mechanism causing the 
genes to lose their tumor suppressive function.  
Various genes have already been identified to help distinguish endometrioid from 
non-endometrioid tumors. For example, EIG121, a gene induced by exogenous and 
endogenous estrogens, is highly elevated in complex atypical hyperplasia and grade 1 
endometrioid carcinomas, but not in non-endometrioid carcinomas, such as MMMT (33). 
Similarly, we found P-cadherin and VAV3 had higher expression levels in endometrioid 
endometrial carcinomas but had a significant decrease in expression in non-endometrioid 
endometrial carcinomas. As a result, these genes would also be especially useful in 
distinguishing endometrioid from non-endometrioid tumors.  
When comparing grade 1 endometrioid tumors to grade 3 endometrioid type tumors, 
PIK3R1, EFNA1, EDNRA, and HES1 showed substantially higher expression levels in grade 
1 endometrioid type tumors. Interestingly, most of these genes were not helpful in 
distinguishing low stage (I and II) form higher stage (III and IV) endometrial carcinomas. 
Only HES1 showed higher expression levels in low stage endometrial carcinomas and 
significantly lower expression levels in high stage endometrial carcinomas. 
 As previously stated, several of the genes validated could potentially be used to help 
distinguish normal endometrium from grade 1 endometrioid adenocarcinoma, as well as low 
grade endometrial carcinomas from high grade endometrial carcinomas. It has been 
observed that for many genes and pathways, there is little difference between normal 
endometrium, complex atypical hyperplasia and grade 1 endometrioid tumors (34, 35). 
Therefore, it can be difficult to distinguish between the three. Also, grade 1 endometrioid 
tumors are well-differentiated, while grade 3 endometrioid tumors are poorly-differentiated 
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and clinically invasive. Gene panels that target these two comparisons would be extremely 
helpful to identify the subset of women who are at-risk for endometrial cancer development 
or for metastasis.  
Oncotype Dx is a qRT-PCR gene panel used to help guide the therapy of women 
with ER positive, lymph node negative -breast cancer. It can be run on formalin-fixed, 
paraffin-embedded tissues. This panel helps to identify the subset of women who might be at 
highest risk for recurrence/metastasis.  These women would then be treated with 
chemotherapy in addition to tamoxifen/aromatase inhibitors (36). Using the genes that had a 
distinct difference in expression between normal endometrium and grade 1 EEC, a similar 
type of qRT-PCR gene panel could be developed in order to identify the subset of women 
who might be at highest risk for endometrial cancer development. qRT-PCR could be 
performed on formalin-fixed, paraffin-embedded benign endometrial biopsies to determine 
the expression levels of OLFM1, EFNA1, EDNRA, HES1, SPRY1, and PIK3R1. The women 
whose tissues have low expression levels of these genes could begin chemoprevention 
counter measures, begin a weight loss program if obese, or consider prophylactic 
hysterectomy to avoid endometrial cancer development. Additionally, another gene panel 
which screens for the genes which have significantly low expression levels in poorly 
differentiated endometrial carcinomas would help to identify women who may be at highest 
risk for metastasis. In this case, women could receive adjuvant treatment following 
hysterectomy to help prevent recurrence or metastasis.  
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Heterogeneity in Cancer 
 Cancer is a heterogeneous disease – pathways active in one cancer type may not be 
active at all in a different type. As a result, the effect or impact of a specific gene may be 
different depending on the specific cancer type. For a number of the genes validated in our 
study, the results in endometrial cancer are very different from what has been reported for 
other cancer types.  
VAV3 is over-expressed in breast and prostate cancers in correlation with poorly 
differentiated tumors (13). However, our study found VAV3 expression to be higher in well-
differentiated endometrial carcinomas and down-regulated in poorly differentiated 
endometrial carcinomas. Increased expression of EFNA1 contributes to tumorigenesis in 
several different cancer types, such as melanoma, bladder, gastric, cervical and ovarian 
cancers (21). However, we found EFNA1 expression to be down-regulated in correlation 
with poorly differentiated endometrial carcinomas. EDNRA and HES1 over-expression is 
also correlated with high grade ovarian carcinomas (23, 27), but the opposite is seen in high 
grade endometrial carcinomas. Additionally, HEYL expression is higher in invasive breast 
cancers (25), but we found HEYL to be down-regulated in the more clinically invasive and 
poorly differentiated endometrial carcinomas. Based on these results, the extent of 
heterogeneity in cancer is apparent.  
Studies have reported that almost 90% of signaling pathways are different in cells of 
various cancers (37). What causes a pathway to be active in one cancer type but not active in 
another type? While there is no definite explanation, many possibilities have been 
suggested. The outcome could be dependent on the specific cell type, chronology of the 
mutation, or that the intermediate proteins of a signaling pathway are different from one 
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cancer type to another. Regardless, it is important to keep in mind that cancers can be 
heterogeneous and develop in a different manner. Drugs or therapies targeted for one cancer 
type therefore may not have the same successful outcome on another cancer type.   
 
Notch Role in Cancer 
Some signaling pathways have been reported to have both tumor suppressive and 
tumor promoting roles. For example, TGF-β can act as an oncogene or as a tumor suppressor 
in a context dependent manner. Typically, early in tumorigenesis, TGF-β acts as a tumor 
suppressor, functioning to inhibit proliferation, induct apoptosis, activate autophagy, induct 
senescence, inhibit motility and promote differentiation (38). However, as tumors progress, 
epigenetic and genetic changes to the tumor cell genome cause TGF-β to switch from a 
tumor suppressor to a tumor promoter. These epigenetic and genetic changes include loss of 
Smad4, overexpression of Six1, down-regulation of DAB2, and p53 mutation. As a result, 
later in tumorigenesis, TGF-β promotes proliferation, epithelial to mesenchymal transition, 
metastasis, and cell motility (38). Inactivation of the vital TGF-β pathway members, such as 
TGF-β receptors, is also responsible for disabling the tumor suppressive effect of TGF-β. 
This occurs in colorectal, pancreatic, ovarian, and gastric cancers (39).  
The Notch signaling pathway also has both oncogenic and tumor suppressive roles in 
various cancers. There is much debate as to why Notch acts differently in different tissues. 
Because p21 induction typically inhibits cell growth, one possible explanation is that its role 
is dependent on the status of the G1 cell cycle checkpoint. p21 is responsible for the 
formation of the cyclinD/CDK4 complex, but it does not inactivate the complex. However, 
p21 does inactivate the CDK2/cyclin E complex and is also responsible for CDK4-
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dependent Rb phosphorylation. Therefore, the expression levels of p21, cyclin D1, cyclin E, 
and CDKs 4, 5, and 2 determine whether Notch activation causes cell growth or growth 
arrest. For example, if the G1 checkpoint is inactivated by loss of p16 or up-regulation of D 
cyclins, Notch-1 mediated induction of p21 may not inhibit cell growth. (40) 
 
Notch as an oncogene 
Notch involvement in cancer was first seen in T-acute lymphoblastic 
leukemia/lymphoma (T-ALL) in 1991. A translocation was found in T-ALL patients, which 
caused the fusion of the 3’ region of Notch1 into the TCRβ locus and led to overexpression 
of the activated form of Notch1. The translocation seemed to be rare, but several years later, 
activating Notch1 mutations were seen in about 56% of T-ALL patients. (30, 31) 
After this discovery, Notch signaling was linked to several solid tumors, including 
breast cancer, medulloblastoma, colorectal cancer, non-small cell lung cancer, and 
melanomas (31). Notch’s oncogenic potential was first seen in mouse mammary tumor virus 
(MMTV) driven breast cancer. Studies have shown that incorporating MMTV in specific 
loci caused dysregulated expression of adjacent genes and growth of tumorigenic clones. 
Loci characterization revealed a constitutively active form of Notch4. Therefore, Notch 
activation evidently causes mammary tumors in mouse models and in human breast cancer, 
Notch or Jag1 up-regulation has been reported to correlate with poor prognosis (31).  
The expression of Notch receptors and their target genes is also up-regulated in 
primary human melanomas, in which constitutively active Notch1 promotes melanoma 
progression. The oncogenic role of Notch in melanoma cells correlates with the activation of 
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Wnt signaling. Increased Notch activity in melanoma cells has also been correlated with 
activation of the PI3K/Akt signaling pathway. (30)  
 
Notch as a tumor suppressor 
Studies have shown the tumor suppressive functions of Notch to occur through 
several mechanisms. First, it seems that one Notch target gene, p21, contributes to its tumor 
suppressive effects through inhibiting Wnt4a expressions and Wnt signaling in normal 
epithelium. It is also possible there is negative cross talk between Notch and p63, leading to 
deregulation of the balance between differentiation and self-renewal. (30) 
The conditional deletion of Notch1 results in an increase of the basal epidermal layer 
in the skin. Notch1 loss of function has also been reported to result in spontaneous basal cell 
carcinomas in older mice. Additionally, the combined deletion of Notch1 and Notch2 or the 
conditional Notch loss-of-function through the deletion of Nicastrin, a vital component of 
the gamma-secretase complex, results in a myeloproliferative syndrome with common 
features of chronic myelomonocytic leukemia. (30) 
Studies have also reported Notch to act as a tumor suppressor in head and neck 
squamous cell carcinomas (HNSCC). Out of 21/120 patients analyzed, Agrawal et al. (41) 
identified 28 different Notch1 mutations, 11 of which were insertion/deletions or nonsense 
mutations resulting in Notch loss-of-function. Another study by Stransky et al. (42) 
identified Notch1 mutations in 11% of HNSCC patients analyzed, with an additional 11% of 
patients having Notch2 or Notch3 mutations. The mutations in this study were missense, 
nonsense, or insertion/deletions which targeted the extracellular domain of the Notch 
receptors, leading to loss-of-function. Furthermore, Notch suppresses growth and induces 
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apoptosis in B cell tumors, providing additional evidence of tumor suppressive functions of 
the Notch pathway. (31) 
 
Notch and Endometrial Cancer 
The human endometrium undergoes tissue remodeling due to hormonal changes 
during every reproductive cycle. As a result, angiogenesis, the formation of new blood 
vessels, contributes to the remodeling of the endometrium. Deregulation of angiogenesis and 
the factors that promote or inhibit it relates to histological differentiation and may 
predispose endometrial cells to become malignant. The Notch pathway has been reported to 
contribute to angiogenesis and tissue remodeling. (32) 
Cobellis et al. (32) investigated the localization and pattern of expression of Notch 
components, Notch1, Notch4, and Jagged1, in physiological and pathological human 
endometrium. Through immunohistochemistry, they found both Notch1 and Notch4 to have 
moderate expression levels in the glandular epithelium during the proliferative phase but 
observed an increase in Notch1 expression and a decrease in Notch4 expression during the 
secretory phase. Jagged1 had low expression levels in both the proliferative and secretory 
phases of the physiological endometrium examined. In the pathological specimens examined 
through immunohistochemistry, there was an increase in expression of Notch1 from polyps 
to carcinomas while both Notch4 and Jagged1 decreased in expression. It should be noted 
that the immunohistochemical expression for Notch pathway members, even in the normal 
endometrium, was very faint in the photomicrographs presented. This calls into question the 
reliability of the antibodies used for this study. It is possible the immunohistochemistry is 
underestimating the expression of Notch pathway components in the normal endometrium.   
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The results reported by Cobellis et al. (32) on the decrease in expression levels of 
Notch4 and Jagged1 from polyps to endometrial carcinomas are similar to the results we 
found through qRT-PCR. Both of these results suggest that Notch4 and Jagged1 could 
function as tumor suppressor proteins in the human endometrium and deregulation of these 
functions could lead to cancer.  
The Notch pathway has been reported to contribute to cell differentiation, 
angiogenesis and vascularization. Because the endometrium undergoes tissue remodeling 
during the reproductive cycle, it is important to effectively regulate the factors that 
contribute to this process. Inhibition or inactivation of the factors that are involved in cell 
differentiation and angiogenesis is a possible reason for tumor progression in endometrial 
cancer. Further studies are needed on the cross talk between Notch components and factors 
responsible for differentiation and angiogenesis in order to understand the complete 
mechanism for endometrial cancer development. 
 
Clinical Implications of Targeting the Notch Pathway 
 
Clinically useful agonists that activate the Notch pathway have not yet been 
described. However, there are a variety of genetic and pharmacological therapies that can 
inhibit Notch signaling at different levels of the pathway. Notch receptors and ligands can be 
inhibited by selective and non-selective strategies such as monoclonal antibodies, receptor 
decoys, soluble ligands, or inhibition of enzymes responsible for receptor cleavage, such as 
gamma secretase inhibitors or ADAM inhibitors. (29) 
Gamma secretase inhibitors (GSIs) are the furthest in development as possible cancer 
treatment agents. GSIs function by inhibiting the gamma secretase complex, which normally 
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cleaves Notch into its active form. Through inhibiting this process, Notch remains inactive 
and further signaling is stopped. Merck and Roche have entered GSIs into clinical trials. In a 
phase I trial, GSI MK-0752 (Merck) was given to 7 patients with advanced solid tumors and 
14 patients with advanced breast cancer. At all doses, MK-0752, inhibited gamma secretase 
and decreased Abeta40, a product of gamma secretase cleavage, by 46% (29). GSIs have 
also shown antitumor activity in several human cancer cell lines. They have reduced tumor 
growth and vasculature in glioblastoma and lung cancer cell lines, induced growth arrest in 
T-ALL cells, and induced apoptosis in melanoma cell lines. (29) 
 
Limitations 
Although the research has reached its aims, there were some limitations to this study. Due to 
the lack of commercially available antibodies for the Notch pathway components, we were 
unable to perform immunohistochemistry to test for the protein levels of Notch components 
in normal and endometrial cancer samples. Also, since we were unable to perform this 
technique, it was difficult to compare our results to published literature that employed 
immunohistochemistry to determine Notch function in endometrial cancer. One approach 
that could help in localization would be to design in situ hybridization or fluorescent in situ 
hybridization probes for some of the relevant Notch pathway components. Finally, the 
amount of normal endometrial tissue samples and grade 1 endometrial carcinomas tissue 
samples available for this study was low due to lack of patients admitted to MD Anderson 
Cancer Center with benign lesions or low grade tumors. 
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